John A Bittl Selected Research

Secondary Prevention

9/2016	Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
1/2016	Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John A Bittl Research Topics

Disease

20	Hemorrhage 01/2018 - 02/2003
12	Myocardial Infarction 11/2018 - 02/2003
11	ST Elevation Myocardial Infarction 01/2021 - 04/2013
9	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022 - 06/2013
8	Thrombosis (Thrombus) 09/2016 - 03/2006
6	Myocardial Ischemia (Ischemic Heart Diseases) 01/2022 - 11/2014
6	Acute Coronary Syndrome 01/2021 - 11/2005
6	Cardiovascular Diseases (Cardiovascular Disease) 11/2016 - 03/2004
4	Stroke (Strokes) 09/2016 - 04/2004
4	Fistula 01/2010 - 11/2005
3	Diabetes Mellitus 08/2017 - 06/2005
3	Infarction (Infarctions) 07/2006 - 08/2002
2	Coronary Disease (Coronary Heart Disease) 01/2022 - 10/2015
2	Chronic Kidney Failure (Chronic Renal Failure) 03/2021 - 01/2010
2	Chronic Renal Insufficiency 09/2015 - 10/2003
2	Pathologic Constriction (Stenosis) 12/2009 - 04/2003
1	Left Ventricular Dysfunction 01/2022
1	Heart Diseases (Heart Disease) 08/2017
1	Rupture 12/2009
1	Anemia 11/2007
1	Unstable Angina 07/2006
1	Atherosclerotic Plaque (Atheroma) 03/2004
1	Thrombocytopenia (Thrombopenia) 01/2003

Drug/Important Bio-Agent (IBA)

12	bivalirudin (Angiomax)FDA Link 01/2017 - 02/2003
12	Heparin (Liquaemin)FDA LinkGeneric 01/2017 - 01/2003
7	Glycoproteins (Glycoprotein)IBA 12/2015 - 02/2003
5	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 08/2017 - 01/2016
4	Proliferating Cell Nuclear Antigen (PCNA)IBA 09/2016 - 11/2014
4	Platelet Membrane Glycoprotein IIbIBA 12/2005 - 02/2003
3	AntithrombinsIBA 12/2005 - 02/2003
2	TicagrelorIBA 11/2018 - 12/2015
2	cangrelorIBA 01/2017 - 03/2006
2	Abciximab (ReoPro)FDA Link 04/2013 - 03/2006
2	CreatinineIBA 11/2007 - 10/2003
1	Clopidogrel (Plavix)FDA Link 01/2017
1	omega-Chloroacetophenone (Mace)IBA 06/2016
1	Prasugrel Hydrochloride FDA Link 12/2015
1	Everolimus FDA Link 09/2015
1	Adenosine Diphosphate (ADP)IBA 03/2006
1	antineoplaston A10 (A 10)IBA 11/2005
1	Eptifibatide (Integrilin)FDA Link 02/2003

Therapy/Procedure

29	Percutaneous Coronary Intervention 01/2022 - 02/2003
15	Therapeutics 01/2022 - 02/2003
9	Stents 09/2016 - 01/2003
6	Renal Dialysis (Hemodialysis) 03/2021 - 04/2003
4	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/2022 - 07/2006
2	Secondary Prevention 09/2016 - 01/2016
2	Catheters 01/2010 - 12/2009
1	Drug-Eluting Stents 08/2017
1	Thrombectomy 06/2016
1	Renal Replacement Therapy (Therapies, Renal Replacement) 01/2010
1	Aftercare (After-Treatment) 03/2004
1	Myocardial Revascularization 08/2002